WE
BEAM icon

Wealth Effects’s Beam Therapeutics BEAM Stock Holding History

Wealth Effects’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$362K Buy
10,549
+449
+4% +$13.6K 0.1% 167
2026
Q1 		$241K Buy
10,100
+500
+5% +$13.9K 0.09% 190
2025
Q4 		$266K Buy
9,600
+400
+4% +$10.2K 0.08% 165
2025
Q3 		$223K Buy
+9,200
New +$183K 0.07% 192
2022
Q1 		– Sell
-2,700
Closed -$215K – 209
2021
Q4 		$215K Buy
+2,700
New +$231K 0.09% 192

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Wealth Effects's BEAM Position: Q2 2026 in Review

Wealth Effects increased its Beam Therapeutics (BEAM) stake by 4.4% in Q2 2026, buying an estimated $13.6K and bringing the position to 10,549 shares worth $362K. The position accounts for 0.1% of the portfolio, ranked #167.

Wealth Effects first reported a position in BEAM in Q4 2021 and has held it in 5 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Wealth Effects held 10,549 shares of Beam Therapeutics worth $362K as of Q2 2026.
  • Wealth Effects bought 449 Beam Therapeutics shares in Q2 2026, an estimated $13.6K.
  • Beam Therapeutics made up 0.1% of Wealth Effects's portfolio in Q2 2026, its #167 holding.
  • Wealth Effects first reported a position in Beam Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Wealth Effects's 13F filing for Q2 2026, filed 6 Aug 2026.